| Autor: |
Packer, Milton, Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Ferreira, Joao Pedro, Pocock, Stuart J, Rocca, Hans-Peter Brunner-La, Janssens, Stefan, Tsutsui, Hiroyuki, Zhang, Jian, Brueckmann, Martina, Jamal, Waheed, Cotton, Daniel, Iwata, Tomoko, Schnee, Janet, Zannad, Faiez, EMPEROR-Reduced Trial Committees and Investigators |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| ISSN: |
0195-668X |
| Popis: |
AIMS: We evaluated the influence of sacubitril/valsartan on the effects of sodium-glucose cotransporter 2 (SGLT2) inhibition with empagliflozin in patients with heart failure and a reduced ejection fraction. METHODS AND RESULTS: The EMPEROR-Reduced trial randomized 3730 patients with heart failure and an ejection fraction ≤40% to placebo or empagliflozin (10 mg/day), in addition to recommended treatment for heart failure, for a median of 16 months. A total of 727 patients (19.5%) received sacubitril/valsartan at baseline. Analysis of the effect of neprilysin inhibition was 1 of 12 pre-specified subgroups. Patients receiving a neprilysin inhibitor were particularly well-treated, as evidenced by lower systolic pressures, heart rates, N-terminal prohormone B-type natriuretic peptide, and greater use of cardiac devices (all P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
